초록

The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I: or a prodrug or pharmaceutically acceptable salt thereof; anda pharmaceutically acceptable carrier.

대표청구항 ▼

1. A method for determining the amount of a compound of formula I present in a human body fluid: wherein R1, R2, R3, R5, R6 and R7 are independently X3R where R is selected from the group consisting of H, halo; optionally substituted saccharide, aliphatic, cycloalkyl, aryl and heteroaryl; —P(O)(ORa)

1. A method for determining the amount of a compound of formula I present in a human body fluid: wherein R1, R2, R3, R5, R6 and R7 are independently X3R where R is selected from the group consisting of H, halo; optionally substituted saccharide, aliphatic, cycloalkyl, aryl and heteroaryl; —P(O)(ORa)(ORb) and —NRaRb, where Ra and Rb are independently H, optionally substituted aliphatic, cycloalkyl, aryl or heteroaryl;X1 and X3 are independently —C(O)O—, —OC(O)—, —C(O)NH—, —NHC(O)—, —OC(O)NH—, —NHC(O)O—, —OS(O)y—, —S(O)y—, —O—, —NHC(O)—, —NHC(O)O—, —S(O)2NH—, a bond or absent; where y is an integer from 0 to 3;R4 is H, (═O); hydroxy; or optionally substituted saccharide, aliphatic, cycloalkyl, aryl or heteroaryl; or —P(O)(ORa)(ORb) or —NRaRb, where Ra and Rb are independently H, or optionally substituted aliphatic, cycloalkyl, aryl or heteroaryl; andX2 is —O— and R8 is optionally substituted saccharide; or X2 is —OS(O)y— or —S(O)y—, where y is an integer from 0 to 3, and R8 is H or optionally substituted aliphatic;the method comprising:a. obtaining a human body fluidb. measuring the amount of the compound of formula I in the human body fluid. 2. The method of claim 1, wherein the compound of formula I is xanthurenic acid-8-O-β-D-glucoside xanthurenic acid 8-O-sulfate. 3. A method for monitoring or detecting a disease associated with an abnormal level of xanthurenic acid-8-O-β-D-glucoside or xanthurenic acid 8-O-sulfate, the method comprising: detecting a level of xanthurenic acid-8-O-β-D-glucoside or xanthurenic acid 8-O-sulfate in a biological sample, wherein an excessive or deficient of level of the compound of formula I in the biological sample is associated with the disease. 4. The method of claim 3, wherein an elevated level of xanthurenic acid-8-O-β-D-glucoside or xanthurenic acid 8-O-sulfate in the biological sample is associated with the disease. 5. The method of claim 3, wherein a deficient level of xanthurenic acid-8-O-β-D-glucoside or xanthurenic acid 8-O-sulfate in the biological sample is associated with the disease. 6. The method of claim 3, wherein said disease is selected from the group consisting of hypertension, edema, acute renal failure, congestive heart failure, chronic renal failure, ascites, increased intra-ocular pressure, nephrotic syndrome or other disease state involving irregularities in fluid/sodium balance. 7. The method of claim 3, wherein said biological sample is a urine sample. 8. The method of claim 3, wherein said biological sample is a serum sample. 9. The method of claim 1, further comprising the step of monitoring or detecting a disease associated with an abnormal level of the compound of formula I.